The Friedrich Miescher Institute for Biomedical Research (FMI), based in Basel, Switzerland, is a world class biomedical research institute dedicated to understanding the molecular mechanisms of health and disease. It is named after Friedrich Miescher, the Basel biochemist who discovered nucleic acids in 1869 – just over 100 years before the FMI was etablished in 1970.
With a staff of about 340 – representing 44 nationalities – and 20 research groups, the FMI’s main areas of focus are Neurobiology, Genome Regulation and Multicellular Systems. In addition, the institute has set up strong technology platforms enabling ambitious, interdisciplinary research, and allowing staff to be trained in the use of state-of-the-art technologies. The FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training early career scientists – graduate students and postdoctoral fellows – is also part of the mission of the FMI. Our PhD and MD-PhD programs attract top international students. The institute is affiliated with the University of Basel, where most of our graduate students are enrolled and where many of our group leaders are employed as professors.
The FMI is also affiliated with the Novartis Institutes for BioMedical Research (NIBR). Our institute receives generous core funding from Novartis, our researchers are involved in numerous collaborations with colleagues at Novartis and Novartis has first right of refusal on intellectual property originating from the FMI. The long-term support of the FMI shows Novartis’ commitment to basic research and the education of young scientists.
Funding is supplemented by competitive grants and fellowships from national and international funding agencies. We are proud of the fact that many FMI group leaders have been awarded prestigious ERC grants (the FMI has the highest success rate for ERC grant application of all European institutions, read more) and that over 20% of postdocs are recipients of an EMBO, HFSP or Marie Curie fellowship.
The FMI is currently led by Professor Dirk Schübeler.